View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 31, 2021

Stoke Therapeutics to start Dravet syndrome therapy trial in UK

Stoke Therapeutics is set to commence a Phase I/IIa ADMIRAL study of its investigational new medicine, STK-001, for treating Dravet syndrome, a severe and progressive genetic epilepsy.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena